natgillin/translations-raw huggingface dataset:
Memantine LEK is a ‘generic medicine’.
Zdravilo Memantine LEK je „generično“ zdravilo.
Memantine LEK is not recommended for children and adolescents under the age of 18 years.
Zdravila Mamantin LEK ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
Memantine LEK is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Memantin LEK uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Memantine LEK should be administered once a day and should be taken at the same time every day.
Zdravilo Memantin LEK je treba jemati enkrat dnevno in ga je treba vzeti ob istem času vsak dan.
Memantine Merz 10 mg film-coated tablets.
Memantine Merz 10 mg filmsko obložene tablete.
Memantine Merz 15 mg film-coated tablets are presented as orange to grey-orange, oval-oblong with imprint ‘15’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 15 mg filmsko obložene tablete so oranžne do sivo oranžne, ovalne in podolgovate z vtisnjeno številko "15" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Memantine Merz 15 mg film-coated tablets.
Memantine Merz 15 mg filmsko obložene tablete.
Memantine Merz 20 mg film-coated tablets are presented as are pale red to grey-red, oval-oblong with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 20 mg filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalne in podolgovate z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Memantine Merz 20 mg film-coated tablets.
Memantine Merz 20 mg filmsko obložene tablete
Memantine Merz 20 mg film-coated tablets.
Memantine Merz 20 mg filmsko obložene tablete.
Memantine Merz 5 mg film-coated tablets are presented as white to off-white, oval-oblong with imprint ‘5’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz 5 mg filmsko obložene tablete so bele do belkaste, ovalne in podolgovate z vtisnjeno številko "5" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Memantine Merz 5 mg film-coated tablets.
Memantine Merz 5 mg filmsko obložene tablete.
Memantine Merz 5 mg/pump actuation, oral solution
Memantine Merz 5 mg/pritisk peroralna raztopina.
Memantine Merz 5 mg/pump actuation, oral solution Memantine hydrochloride
Memantine Merz 5 mg/pritisk peroralna raztopina. memantinijev klorid
Memantine Merz 5 mg/pump actuation, oral solution memantine hydrochloride
Memantine Merz 5 mg/pritisk peroralna raztopina. memantinijev klorid.
Memantine Merz 5mg, 10mg, 15mg, 20 mg film-coated tablets Memantine hydrochloride
Memantine Merz 5 mg, 10 mg, 15 mg, 20 mg filmsko obložene tablete memantinijev klorid
Memantine Merz 5mg, Memantine Merz 10 mg Memantine Merz 15 mg Memantine Merz 20 mg film-coated tablets
Memantine Merz 5 mg, Memantine Merz 10 mg Memantine Merz 15 mg Memantine Merz 20 mg filmsko obložene tablete
Memantine Merz 5mg/pump actuation, oral solution.
Memantine Merz 5 mg/pritisk peroralna raztopina.
Memantine Merz acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Zdravilo Memantine Merz deluje na receptorje NMDA in izboljša prenos živčnih signalov in spomin.
Memantine Merz film-coated tablets are available in blister packs of 14 tablets, 28 tablets, 30 tablets, 42 tablets, 50 tablets, 56 tablets, 98 tablets, 100 tablets, 112 tablets and multipscks of 840 (20 packs of
Memantine Merz filmsko obložene tablete se nahajajo v pretisnih omotih v škatlicah s 14 tabletami, 28 tabletami, 30 tabletami, 42 tabletami, 50 tabletami, 56 tabletami, 98 tabletami, 100 tabletami, 112 tabletami.
Memantine Merz film-coated tablets are presented as pale red to grey-red, oval-oblong film-coated tablets with imprint ‘20’ on one side and imprint ‘MEM’ on the other side.
Memantine Merz filmsko obložene tablete so bledo rdeče do sivo rdeče, ovalno podolgovate, filmsko obložene tablete z vtisnjeno številko "20" na eni strani in vtisnjeno besedo "MEM" na drugi strani.
Memantine Merz film-coated tablets are presented as pale yellow to yellow, oval shaped film-coated tablet with breaking line and engravings "1-0" on one side and "M M" on the other side
Memantine Merz filmsko obložene tablete so bledo rumene do rumene, ovalne, filmsko obložene tablete z razdelilno zarezo in vtisnjeno številko "1 0" na eni strani in besedo "M M" na drugi strani.
Memantine Merz has been studied in three main studies including a total of 1,125 patients with Alzheimer’s disease, some of whom had taken other medicines for their disease in the past.
Zdravilo Memantine Merz so proučevali v treh glavnih študijah, ki so vključevale skupno 1 125 bolnikov z Alzheimerjevo boleznijo, pri čemer so nekateri izmed njih v preteklosti prejemali druga zdravila za zdravljenje te bolezni.
Memantine Merz is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Memantine Merz uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Memantine Merz is used to treat patients with moderate to severe Alzheimer’s disease.
Zdravilo Memantine Merz se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Memantine Merz oral solution is available in bottles of 50 ml, 100 ml or a multipack of 500ml (10 x 50 ml).
Memantine Merz peroralna raztopina je na voljo v stekleničkah po 50 ml, 100 ml ali v večkratnem pakiranju po 500ml (10 x 50 ml).
Memantine Merz should be administered once a day and should be taken at the same time every day.
Zdravilo Memantine Merz je treba dajati enkrat dnevno in ob istem času vsak dan.
Memantine Merz was more effective than placebo at controlling the symptoms of Alzheimer’s disease.
Zdravilo Memantine Merz je bilo pri nadzorovanju simptomov Alzheimerjeve bolezni učinkovitejše od placeba.
Memantine Merz with food and drink
Zdravilo Memantine Merz skupaj s hrano in pijačo
Memantine Mylan belongs to a group of medicines called NMDA- receptor antagonists.
Zdravilo Memantin Mylan spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.
Memantine Mylan contains the active substance memantine.
Zdravilo Memantin Mylan vsebuje zdravilno učinkovino memantin.
Memantine Mylan is a medicine used to treat patients with moderate to severe Alzheimer’s disease, a type of dementia (a brain disorder) that gradually affects memory, intellectual ability and behaviour.
Memantine Mylan je zdravilo, ki se uporablja za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo, vrsto demence (možganske bolezni), ki postopoma prizadene spomin, intelektualno sposobnost in vedenje.
Memantine Mylan is a ‘generic medicine’.
Zdravilo Memantine Mylan je „generično“ zdravilo.
Memantine Mylan is not recommended for children and adolescents under the age of 18 years.
Zdravila Memantin Mylan ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
Memantine Mylan is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Memantin Mylan uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Memantine Mylan should be administered orally once a day.
Zdravilo Memantin Mylan jemljite peroralno enkrat na dan.
Memantine Mylan with food and drink
Zdravilo Memantin Mylan skupaj s hrano in pijačo
Memantine ratiopharm
Memantin ratiopharm
Memantine ratiopharm 10 mg film-coated tablets
Memantin ratiopharm 10 mg filmsko obložene tablete
Memantine ratiopharm 10 mg film-coated tablets Memantine hydrochloride
Memantin ratiopharm 10 mg filmsko obložene tablete memantinijev klorid
Memantine ratiopharm 10 mg tablets Memantine hydrochloride
Memantin ratiopharm 10 mg tablete memantinijev klorid
Memantine ratiopharm 15 mg film-coated tablets Memantine hydrochloride
Memantin ratiopharm 15 mg filmsko obložene tablete memantinijev klorid
Memantine ratiopharm 20 mg film-coated tablets
Memantin ratiopharm 20 mg filmsko obložene tablete
Memantine ratiopharm 20 mg film-coated tablets Memantine hydrochloride
Memantin ratiopharm 20 mg filmsko obložene tablete memantinijev klorid
Memantine ratiopharm 20 mg tablets Memantine hydrochloride
Memantin ratiopharm 20 mg tablete memantinijev klorid
Memantine ratiopharm 5 mg film-coated tablets Memantine hydrochloride
Memantin ratiopharm 5 mg filmsko obložene tablete memantinijev klorid
Memantine ratiopharm 5 mg film-coated tablets Memantine ratiopharm 10 mg film-coated tablets Memantine ratiopharm 15 mg film-coated tablets Memantine ratiopharm 20 mg film-coated tablets Memantine hydrochloride
Memantin ratiopharm 5 mg filmsko obložene tablete Memantin ratiopharm 10 mg filmsko obložene tablete Memantin ratiopharm 15 mg filmsko obložene tablete Memantin ratiopharm 20 mg filmsko obložene tablete memantinijev klorid
Memantine ratiopharm 5 mg Memantine ratiopharm 10 mg Memantine ratiopharm 15 mg Memantine ratiopharm 20 mg film-coated tablets
Memantin ratiopharm 5 mg Memantin ratiopharm 10 mg Memantin ratiopharm 15 mg Memantin ratiopharm 20 mg filmsko obložene tablete
Memantine ratiopharm belongs to a group of medicines known as anti-dementia medicines.
Zdravilo Memantin ratiopharm sodi v skupino zdravil, znanih kot zdravila za zdravljenje demence.
Memantine ratiopharm contains lactose and soya lecithin
Zdravilo Memantin ratiopharm vsebuje laktozo in sojin lecitin
Memantine ratiopharm is a ‘generic medicine’.
Zdravilo Memantine ratiopharm je „generično zdravilo“.
Memantine ratiopharm is not recommended for children and adolescents under the age of 18 years.
Zdravila Memantin ratiopharm ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
Memantine ratiopharm is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Memantin ratiopharm pri otrocih pod 18 let ni priporočljiva.
Memantine ratiopharm is used for the treatment of patients with moderate to severe Alzheimer’s disease.
Zdravilo Memantin ratiopharm uporabljamo za zdravljenje bolnikov z zmerno do hudo Alzheimerjevo boleznijo.
Memantine ratiopharm memantine hydrochloride
Memantine ratiopharm memantinijev klorid
Memantine ratiopharm should be administered once a day and should be taken at the same time every day.
Zdravilo Memantin ratiopharm je treba dati enkrat dnevno in ga je treba zaužiti ob istem času vsak dan.
Memantine ratiopharm with food and drink
Zdravilo Memantin ratiopharm skupaj s hrano in pijačo
Memantine should not be used during pregnancy unless clearly necessary.
Memantina se ne sme uporabljati med nosečnostjo, razen če je nujno potrebno.
Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted on fertility.
Memantin ni bil teratogen pri podganah in kuncih, niti pri odmerkih, toksičnih za mater, prav tako niso opazili neželenih učinkov na rodnost.
Memantine was not teratogenic in rats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted onf ertility.
Memantin ni bil teratogen pri podganah in zajcih, tudi pri odmerkih, toksičnih za mater, prav tako pa niso opazili neželenih učinkov na rodnost.
Memantine was not teratogenic inrats and rabbits, even at maternally toxic doses, and no adverse effects of memantine were noted on fertility.
Memantin ni bil teratogen pri podganah in zajcih, tudi pri odmerkih, toksičnih za mater, prav tako pa niso opazili neželenih učinkov na rodnost.
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer´s disease assessment scale (ADAS-cog) (p=0.003) -and CIBIC-plus (p=0.004) at week 24 last observation carried forward (LOCF).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo pri primarnih ciljih študije: lestvica ocene Alzheimerjeve bolezni (ADAS-cog) (p=0,003) in CIBIC-plus (p=0,004) po 24 tednih prenosa zadnjih opaženih rezultatov naprej (LOCF).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer´s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo pri primarnih ciljih študije: Lestvica za ocenjevanje Alzheimerjeve bolezni (Alzheimer´s disease assessment scale ali ADAS-cog) (p=0,003) in CIBIC-plus (p=0,004) po 24 tednih (last observation carried forward (LOCF)).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer’s disease assessment scale (ADAS-cog) (p = 0.003) and CIBIC-plus (p = 0.004) at week 24 (last observation carried forward (LOCF)).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo, pri primarnih ciljih študije: po lestvici za ocenjevanje Alzheimerjeve bolezni (Alzheimer´s disease assessment scale, ADAS-cog) (p = 0,003) in lestvici CIBIC-plus (p = 0,004) po 24 tednih (last observation carried forward, LOCF).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer’s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo pri primarnih ciljih študije: Lestvica za ocenjevanje Alzheimerjeve bolezni (ADAS-cog) (p=0,003) in CIBIC-plus (p=0,004) po 24 tednih (LOCF).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer’s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo pri primarnih ciljih študije: Lestvica za ocenjevanje Alzheimerjeve bolezni (Alzheimer´s disease assessment scale ali ADAS-cog) (p=0,003) in CIBIC-plus (p=0,004) po 24 tednih (last observation carried forward (LOCF)).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer’s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 last observation carried forward (LOCF).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo pri primarnih ciljih študije: lestvica ocene Alzheimerjeve bolezni (ADAS-cog) (p=0,003) in CIBIC-plus (p=0,004) po 24 tednih prenosa zadnjih opaženih rezultatov naprej (LOCF).
Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer’s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24last observation carried forward (LOCF).
Pri bolnikih, zdravljenih z memantinom, se je pokazal statistično značilno boljši učinek kot pri bolnikih, ki so prejemali placebo pri primarnih ciljih študije: lestvica ocene Alzheimerjeve bolezni (ADAS-cog) (p=0,003) in CIBIC-plus (p=0,004) po 24 tednih prenosa zadnjih opaženih rezultatov naprej (LOCF).
Memory impairment
motnje spomina
Memory impairment
motnje spomina;
Memory impairment/ Memory loss
motnje spomina/izguba spomina
Memory impairment/Memory loss
motnje spomina/izguba spomina
Memory impairment; dizziness.
Motnje spomina; omotica.
Memory loss
izguba spomina
Memory loss
izguba spomina,
memory loss
izguba spomina;
Memory loss
izgubi spomina,
memory loss
poslabšanje spomina
Memory loss (dementia)
izguba spomina (demenca);
Memory loss Dizziness Hypoaesthesia Sciatica Paresthesia
poslabšanje spomina omotica hipestezija išias parestezija
Memory loss in Alzheimer’s disease is due to a disturbance of message signals in the brain.
Izguba spomina pri Alzheimerjevi bolezni nastane zaradi motenj v prenosu signalov v možganih.
Memory loss or forgetfulness
izgubo spomina ali pozabljivost
memory loss, coma, neuroleptic malignant syndrome (inability to move, sweating, fever, incontinence), status epilepticus (prolonged or repeated seizures)
izguba spomina, koma, nevroleptični maligni sindrom (nezmožnost gibanja, znojenje, vročina, inkontinenca), epileptični status (dolgotrajen ali ponavljajoč se napad krčev);
memory loss, disturbed or depressed mood, lack of energy, generally feeling unwell
izguba spomina, motnje razpoloženja ali depresivno razpoloženje, pomanjkanje energije, splošno slabo počutje
memory problems
težave s spominom,
memory problems (amnesia)
težave s spominom (amnezija),
Men
Moški:
Men and women of childbearing potential must use effective contraception during treatment with TRISENOX.
Moški in ženske v rodni dobi morajo uporabljati učinkovito kontracepcijo med zdravljenjem z zdravilom TRISENOX.
Men and women should use effective contraception during treatment and for at least 6 months after Oncaspar discontinuation.
Moški in ženske morajo med zdravljenjem in še najmanj 6 mesecev po prekinitvi zdravljenja z zdravilom Oncaspar uporabljati učinkovito kontracepcijo.
Men and women who can father or have children should use effective contraception: during treatment with ZALTRAP and for at least 6 months after the last dose of treatment.
Moški in ženske, ki bi lahko zaplodili in imeli otroke, morajo uporabljati učinkovito kontracepcijo: med zdravljenjem z zdravilom ZALTRAP in vsaj še 6 mesecev po zadnjem odmerku tega zdravila.
Men having Topotecan Eagle who wish to father a child should ask their doctor for family planning advice.
Moški, ki uporabljajo zdravilo Topotekan Eagle in želijo zaploditi otroka, se morajo z zdravnikom posvetovati glede načrtovanja družine.
Men in fertile age must use effective contraception during treatment and 5 months after treatment (see section 4.4).
Moški v plodni dobi morajo med zdravljenjem in še 5 mesecev po njem uporabljati učinkovito zaščito pred zanositvijo (glejte poglavje 4.4).
Men in fertile age must use effective contraception during treatment and 5 months after treatment (see section 4.6).
Moški v plodni dobi naj učinkovito zaščito pred zanositvijo uporabljajo med zdravljenjem in še 5 mesecev po njem (glejte poglavje 4.6).
Men must not donate semen during treatment with CellCept and for at least 90 days after stopping treatment.
Bolniki med zdravljenjem in vsaj še 90 dni po končanem zdravljenju z zdravilom CellCept ne smete darovati sperme.
Men must take adequate contraceptive precautions during therapy and for at least three months after treatment.
Moški morajo med zdravljenjem in do tri mesece po njem uporabljati ustrezno kontracepcijo.
Men should also use effective contraception during treatment with TRISENOX.
Med zdravljenjem z zdravilom TRISENOX morajo tudi moški uporabljati zanesljiva kontracepcijska sredstva.
Men should not father a child while using Dacogen.
Moški v času uporabe zdravila Dacogen ne smejo spočeti otroka.
Men should practice barrier birth control methods during and for 3 months after treatment with Vistide.
Moški morajo uporabljati pregradno kontracepcijsko zaščito med zdravljenjem z zdravilom Vistide in do 3 mesece po njem.
Men should use effective contraception during treatment and for up to 3 months after treatment has stopped.
Moški morajo uporabljati učinkovito kontracepcijo v času zdravljenja in do 3 mesece po zaključku zdravljenja.
Men taking Odomzo must always use condoms for sex with female partners and for 6 months after stopping treatment.
Moški, ki jemljejo zdravilo Odomzo, morajo med zdravljenjem in 6 mesecev po njegovi prekinitvi vedno uporabljati kondome, kadar imajo spolne odnose z ženskami.
Men vaccinated with Gardasil at 16-26 years of age in Protocol 020 base study will be followed up to 10 years in an extension study.
Moške, cepljene s cepivom Gardasil v starosti od 16 do 26 let v izhodiščni študiji po protokolu 020, bodo v podaljšanju študije spremljali do 10 let.
Men vaccinated with Silgard at 16-26 years of age in Protocol 020 base study will be followed up to 10 years in an extension study.
Moške, cepljene s cepivom Silgard v starosti od 16 do 26 let v izhodiščni študiji po protokolu 020, bodo v podaljšanju študije spremljali do 10 let.
men who are at an increased risk of fractures; men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).
moških s povečanim tveganjem za zlom; moških in ženskah, ki imajo povečano tveganje za zlome zaradi dolgotrajnega zdravljenja z glukokortikoidi (vrsto steroida).
Men who take too much Levitra may experience more side effects or may get severe back pain.
Pri moških, ki so vzeli večji odmerek, se lahko pojavi več neželenih učinkov ali pa hude bolečine v križu.
Men who take too much Sildenafil ratiopharm may experience more side effects or may get severe muscle pain.
Moški, ki vzamejo preveč zdravila Sildenafil ratiopharm, imajo lahko več neželenih učinkov ali hudo bolečino v mišicah.
Men who take too much Vivanza may experience more side effects or may get severe back pain.
Pri moških, ki so vzeli večji odmerek, se lahko pojavi več neželenih učinkov ali pa hude bolečine v križu.
Men wishing to father a child should contact their doctor who may advise them to stop taking Leflunomide Teva and take certain medicines to remove Leflunomide Teva rapidly and sufficiently from their body.
Moški, ki želijo zapoloditi otroka, se morajo posvetovati z zdravnikom, ki jim bo morda svetoval, da nehajo jemati zdravilo Leflunomid Teva in vzamejo določena zdravila za pospešitev izločanja zdravila Leflunomid Teva iz telesa.
Men wishing to father a child should contact their doctor who may advise them to stop taking Leflunomide Winthrop and take certain medicines to remove Leflunomide Winthrop rapidly and sufficiently from their body.
Moški, ki želijo zaploditi otroka, se morajo posvetovati z zdravnikom, ki jim bo morda svetoval, da nehajo jemati zdravilo Leflunomid Winthrop in vzamejo določena zdravila za hitro in uspešno izločanje zdravila Leflunomid Winthrop iz telesa.
Men wishing to father a child should contact their doctor who may advise them to stop taking Repso and take certain medicines to remove Repso rapidly and sufficiently from their body.
Moški, ki želijo zapoloditi otroka, se morajo posvetovati z zdravnikom, ki jim bo morda svetoval, da nehajo jemati zdravilo Repso in vzamejo določena zdravila za hitro in uspešno izločanje zdravila Repso iz telesa.
Men wishing to father a child should contact their doctorwho may advise them to stop taking Leflunomide medac and take certain medicines to remove Leflunomide medac rapidly and sufficiently from their body.
Moški, ki želijo zaploditi otroka, se morajo posvetovati z zdravnikom, ki jim bo morda svetoval, da nehajo jemati zdravilo Leflunomid medac in vzamejo določena zdravila za hitro in uspešno izločanje zdravila Leflunomid medac iz telesa.
Men with diabetes
Moški s sladkorno boleznijo
Men with partners of childbearing potential should use medically acceptable contraception while taking Torisel.
Moški s partnericami v rodni dobi morajo v obdobju, ko dobivajo zdravilo Torisel, uporabljati medicinsko sprejemljivo kontracepcijo.
Men with Peyronie’s disease may have an erection that is curved or bent.
Moški s Peyroniejevo boleznijo imajo lahko erekcijo, ki je ukrivljena ali upognjena.
Men with renal impairment
Moški z okvaroledvic
Men – keep using contraception for 4 months after.
Moški – kontracepcijo uporabljajte še 4 mesece po koncu zdravljenja.
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.1, Avenue de la Gare, L-1611
Menarini International Operations Luxembourg S.A. 1, Avenue de la Gare, L-1611Luxembourg Luksemburg
MenC-CRM vaccine
cepivo MenC-CRM